The article atai Life Sciences Presents Phase 1 Study Data on GRX-917 was originally published on Microdose.
Earlier this year, atai Life Science company GABA Therapeutics announced Positive Final Results from Phase 1 trial of GRX-917.
GRX-917 is a deuterated version of etifoxine, an anxiolytic already approved in France, with rapid onset and efficacy comparable to leading benzodiazepines like alprazolam and lorazepam. The drug is being developed with the aim to treat conditions like generalized anxiety disorder (GAD), anxious depression, social anxiety disorder (SAD), panic disorder, and postpartum depression.
According to atai “GRX-917 will offer a differentiated treatment for GAD with fewer side effects—such as sedation, respiratory depression, and withdrawal.”
For more context on this compound and its potential, atai presented data from its trial yesterday at the Society for Biological Psychiatry (SOBP) Annual Meeting.
It’s pretty heavy on the science, but according to atai the data shows GRX-917 was safe and well-tolerated, with sedation comparable to placebo. See the presentation below.
